Appendix 3Y x 5
Released
Released
Announcement PDF
Appendix 3Y
Change of Director’s Interest Notice
Appendix 3Y
Rule 3.19A.2
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information
and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
IMAGION BIOSYSTEMS LIMITED
ABN
42 616 305 027
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director
Michael HARSH
Date of last notice
14 June 2018
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Direct or indirect interest
Direct
Nature of indirect interest
(including registered holder)
N/A
Date of change
24 June 2019
Note: Provide details of the circumstances giving rise to the relevant
interest.
No. of securities held prior to change
•
150,000 Performance Rights, issued
under the Company’s Long Term
Incentive Plan (LTI), and automatically
vesting into Shares on a one-for one
basis on the vesting date, being 24
months after the Company was
officially quoted.
•
Class
50,000 Performance Rights, issued
under the Company’s Incentive Stock
Option Plan (ISO), and automatically
vesting into Shares on a one-for one
basis on the vesting date, being 6 June
2020.
i) Fully Paid Ordinary Shares (Shares)
ii) Performance Rights
Number acquired
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
i) 150,000 Shares
Appendix 3Y
Change of Director’s Interest Notice
Number disposed
ii) 150,000 Performance Rights
Value/Consideration
150,000 Performance Rights were released
from escrow and automatically vested on 24
June 2019. The Performance Rights then
converted into Shares at nil exercise price
pursuant to the conditions outlined in the
Replacement Prospectus dated 21 June
2017.
• 150,000 Shares
Note: If consideration is non-cash, provide details and estimated
valuation
No. of securities held after change
•
Nature of change
Example: on-market trade, off-market trade, exercise of options,
issue of securities under dividend reinvestment plan, participation in
buy-back
50,000 Performance Rights, issued
under the Company’s ISO, and
automatically vesting into Shares on a
one-for one basis on the vesting date,
being 6 June 2020.
Performance Rights under the LTI Plan have
vested, and converted into fully paid ordinary
shares
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
Date of change
N/A
No. and class of securities to which interest related prior to change
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Interest after change
N/A
Note: Details are only required for a contract in relation to which the interest has changed
Note: If consideration is non-cash, provide details and an estimated valuation
N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed above traded
during a +closed period where prior written clearance was required?
If so, was prior written clearance provided to allow the trade to
proceed during this period?
No
If prior written clearance was provided, on what date was this
provided?
N/A
N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Appendix 3Y
Rule 3.19A.2
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information
and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
IMAGION BIOSYSTEMS LIMITED
ABN
42 616 305 027
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director
John HAZLE
Date of last notice
30 July 2018
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Direct or indirect interest
Direct
Nature of indirect interest
(including registered holder)
N/A
Date of change
24 June 2019
No. of securities held prior to change
150,000 Performance Rights, issued under
the Company’s Long Term Incentive Plan
(LTI), and automatically vesting into Shares
on a one-for one basis on the vesting date,
being 24 months after the Company was
officially quoted.
Class
Fully Paid Ordinary Shares (Shares)
Number acquired
150,000 Shares
Number disposed
150,000 Performance Rights
Value/Consideration
150,000 Performance Rights were released
from escrow and automatically vested on 24
June 2019. The Performance Rights then
converted into Shares at nil exercise price
pursuant to the conditions outlined in the
Replacement Prospectus dated 21 June
2017.
Note: Provide details of the circumstances giving rise to the relevant
interest.
Note: If consideration is non-cash, provide details and estimated
valuation
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
Appendix 3Y
Change of Director’s Interest Notice
No. of securities held after change
150,000 Shares
Nature of change
Performance Rights under the LTI Plan have
vested, and converted into fully paid ordinary
shares
Example: on-market trade, off-market trade, exercise of options,
issue of securities under dividend reinvestment plan, participation in
buy-back
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
Date of change
N/A
No. and class of securities to which interest related prior to change
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Interest after change
N/A
Note: Details are only required for a contract in relation to which the interest has changed
Note: If consideration is non-cash, provide details and an estimated valuation
N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed above traded
during a +closed period where prior written clearance was required?
If so, was prior written clearance provided to allow the trade to
proceed during this period?
No
If prior written clearance was provided, on what date was this
provided?
N/A
N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Appendix 3Y
Rule 3.19A.2
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information
and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
IMAGION BIOSYSTEMS LIMITED
ABN
42 616 305 027
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director
David LUDVIGSON
Date of last notice
14 June 2018
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Direct or indirect interest
Direct
Nature of indirect interest
(including registered holder)
N/A
Date of change
24 June 2019
Note: Provide details of the circumstances giving rise to the relevant
interest.
No. of securities held prior to change
•
150,000 Performance Rights, issued
under the Company’s Long Term
Incentive Plan (LTI), and automatically
vesting into Shares on a one-for one
basis on the vesting date, being 24
months after the Company was
officially quoted.
•
Class
50,000 Performance Rights, issued
under the Company’s Incentive Stock
Option Plan (ISO), and automatically
vesting into Shares on a one-for one
basis on the vesting date, being 6 June
2020.
i) Fully Paid Ordinary Shares (Shares)
ii) Performance Rights
Number acquired
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
i) 150,000 Shares
Appendix 3Y
Change of Director’s Interest Notice
Number disposed
ii) 150,000 Performance Rights
Value/Consideration
150,000 Performance Rights were released
from escrow and automatically vested on 24
June 2019. The Performance Rights then
converted into Shares at nil exercise price
pursuant to the conditions outlined in the
Replacement Prospectus dated 21 June
2017.
• 150,000 Shares
Note: If consideration is non-cash, provide details and estimated
valuation
No. of securities held after change
•
Nature of change
Example: on-market trade, off-market trade, exercise of options,
issue of securities under dividend reinvestment plan, participation in
buy-back
50,000 Performance Rights, issued
under the Company’s ISO, and
automatically vesting into Shares on a
one-for one basis on the vesting date,
being 6 June 2020.
Performance Rights under the LTI Plan have
vested, and converted into fully paid ordinary
shares
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
Date of change
N/A
No. and class of securities to which interest related prior to change
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Interest after change
N/A
Note: Details are only required for a contract in relation to which the interest has changed
Note: If consideration is non-cash, provide details and an estimated valuation
N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed above traded
during a +closed period where prior written clearance was required?
If so, was prior written clearance provided to allow the trade to
proceed during this period?
No
If prior written clearance was provided, on what date was this
provided?
N/A
N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Appendix 3Y
Rule 3.19A.2
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information
and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
IMAGION BIOSYSTEMS LIMITED
ABN
42 616 305 027
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director
Jovanka NAUMOSKA
Date of last notice
14 June 2018
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Direct or indirect interest
Direct
Nature of indirect interest
(including registered holder)
N/A
Date of change
24 June 2019
Note: Provide details of the circumstances giving rise to the relevant
interest.
No. of securities held prior to change
•
150,000 Performance Rights, issued
under the Company’s Long Term
Incentive Plan (LTI), and automatically
vesting into Shares on a one-for one
basis on the vesting date, being 24
months after the Company was
officially quoted.
•
Class
50,000 Performance Rights, issued
under the Company’s Incentive Stock
Option Plan (ISO), and automatically
vesting into Shares on a one-for one
basis on the vesting date, being 6 June
2020.
i) Fully Paid Ordinary Shares (Shares)
ii) Performance Rights
Number acquired
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
i) 150,000 Shares
Appendix 3Y
Change of Director’s Interest Notice
Number disposed
ii) 150,000 Performance Rights
Value/Consideration
150,000 Performance Rights were released
from escrow and automatically vested on 24
June 2019. The Performance Rights then
converted into Shares at nil exercise price
pursuant to the conditions outlined in the
Replacement Prospectus dated 21 June
2017.
• 150,000 Shares
Note: If consideration is non-cash, provide details and estimated
valuation
No. of securities held after change
•
Nature of change
Example: on-market trade, off-market trade, exercise of options,
issue of securities under dividend reinvestment plan, participation in
buy-back
50,000 Performance Rights, issued
under the Company’s ISO, and
automatically vesting into Shares on a
one-for one basis on the vesting date,
being 6 June 2020.
Performance Rights under the LTI Plan have
vested, and converted into fully paid ordinary
shares
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
Date of change
N/A
No. and class of securities to which interest related prior to change
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Interest after change
N/A
Note: Details are only required for a contract in relation to which the interest has changed
Note: If consideration is non-cash, provide details and an estimated valuation
N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed above traded
during a +closed period where prior written clearance was required?
If so, was prior written clearance provided to allow the trade to
proceed during this period?
No
If prior written clearance was provided, on what date was this
provided?
N/A
N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Appendix 3Y
Change of Director’s Interest Notice
Appendix 3Y
Rule 3.19A.2
Change of Director’s Interest Notice
Information or documents not available now must be given to ASX as soon as available. Information
and documents given to ASX become ASX’s property and may be made public.
Introduced 30/09/01 Amended 01/01/11
Name of entity
IMAGION BIOSYSTEMS LIMITED
ABN
42 616 305 027
We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for
the director for the purposes of section 205G of the Corporations Act.
Name of Director
Mark VAN ASTEN
Date of last notice
14 June 2018
Part 1 - Change of director’s relevant interests in securities
In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust
Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Direct or indirect interest
Direct
Nature of indirect interest
(including registered holder)
N/A
Date of change
24 June 2019
Note: Provide details of the circumstances giving rise to the relevant
interest.
No. of securities held prior to change
•
150,000 Performance Rights, issued
under the Company’s Long Term
Incentive Plan (LTI), and automatically
vesting into Shares on a one-for one
basis on the vesting date, being 24
months after the Company was
officially quoted.
•
Class
50,000 Performance Rights, issued
under the Company’s Incentive Stock
Option Plan (ISO), and automatically
vesting into Shares on a one-for one
basis on the vesting date, being 6 June
2020.
i) Fully Paid Ordinary Shares (Shares)
ii) Performance Rights
Number acquired
+ See chapter 19 for defined terms.
01/01/2011 Appendix 3Y Page 1
i) 150,000 Shares
Appendix 3Y
Change of Director’s Interest Notice
Number disposed
ii) 150,000 Performance Rights
Value/Consideration
150,000 Performance Rights were released
from escrow and automatically vested on 24
June 2019. The Performance Rights then
converted into Shares at nil exercise price
pursuant to the conditions outlined in the
Replacement Prospectus dated 21 June
2017.
• 150,000 Shares
Note: If consideration is non-cash, provide details and estimated
valuation
No. of securities held after change
•
Nature of change
Example: on-market trade, off-market trade, exercise of options,
issue of securities under dividend reinvestment plan, participation in
buy-back
50,000 Performance Rights, issued
under the Company’s ISO, and
automatically vesting into Shares on a
one-for one basis on the vesting date,
being 6 June 2020.
Performance Rights under the LTI Plan have
vested, and converted into fully paid ordinary
shares
Part 2 – Change of director’s interests in contracts
Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should
be disclosed in this part.
Detail of contract
N/A
Nature of interest
N/A
Name of registered holder
(if issued securities)
Date of change
N/A
No. and class of securities to which interest related prior to change
N/A
Interest acquired
N/A
Interest disposed
N/A
Value/Consideration
N/A
Interest after change
N/A
Note: Details are only required for a contract in relation to which the interest has changed
Note: If consideration is non-cash, provide details and an estimated valuation
N/A
Part 3 – +Closed period
Were the interests in the securities or contracts detailed above traded
during a +closed period where prior written clearance was required?
If so, was prior written clearance provided to allow the trade to
proceed during this period?
No
If prior written clearance was provided, on what date was this
provided?
N/A
N/A
+ See chapter 19 for defined terms.
Appendix 3Y Page 2
01/01/2011
Share your feedback
Discover